modelAdefovirDipivoxil
Extends from Pharmacolibrary.Drugs.ATC.J.J05AF08.
Information
| name: | AdefovirDipivoxil | |
| ATC code: | J05AF08 | route: | oral |
| compartments: | 1 | |
| dosage: | 10 | mg |
| volume of distribution: | 392 | L |
| clearance: | 13.6 | L/h |
| other parameters in model implementation | ||
Adefovir dipivoxil is an oral nucleotide analog reverse transcriptase inhibitor formerly approved for the treatment of chronic hepatitis B virus (HBV) infection in adults. Due to risk of nephrotoxicity and availability of more effective treatments, its use has been largely discontinued in favor of safer alternatives. It works by inhibiting HBV polymerase, suppressing viral replication.
Pharmacokinetics
Pharmacokinetics in healthy adult male and female volunteers after oral administration. Parameters are based on published clinical pharmacokinetic studies.
References
Huang, J, et al., & Zheng, Q (2014). Population pharmacokinetics of adefovir dipivoxil tablets in healthy Chinese volunteers. International journal of clinical pharmacology and therapeutics 52(1) 8–14. DOI:10.5414/CP201928 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24219967
Fok, BS, et al., & Tomlinson, B (2013). Pharmacokinetic properties of single-dose lamivudine/adefovir dipivoxil fixed-dose combination in healthy Chinese male volunteers. Clinical therapeutics 35(1) 68–76. DOI:10.1016/j.clinthera.2012.12.001 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23274144
Pfister, M, et al., & Sheiner, LB (2003). Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrobial agents and chemotherapy 47(1) 130–137. DOI:10.1128/AAC.47.1.130-137.2003 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12499180
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)